WO2003030928A3 - Antitumor preparation - Google Patents

Antitumor preparation Download PDF

Info

Publication number
WO2003030928A3
WO2003030928A3 PCT/EP2002/011249 EP0211249W WO03030928A3 WO 2003030928 A3 WO2003030928 A3 WO 2003030928A3 EP 0211249 W EP0211249 W EP 0211249W WO 03030928 A3 WO03030928 A3 WO 03030928A3
Authority
WO
WIPO (PCT)
Prior art keywords
antitumor preparation
antitumor
preparation
cancer
treatment
Prior art date
Application number
PCT/EP2002/011249
Other languages
French (fr)
Other versions
WO2003030928A2 (en
Inventor
Carlo Ciaiolo
Original Assignee
Carlo Ciaiolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlo Ciaiolo filed Critical Carlo Ciaiolo
Publication of WO2003030928A2 publication Critical patent/WO2003030928A2/en
Publication of WO2003030928A3 publication Critical patent/WO2003030928A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3

Abstract

The invention regards a combination of anticancer agents and growth factors for use in the treatment of cancer.
PCT/EP2002/011249 2001-10-09 2002-10-08 Antitumor preparation WO2003030928A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001TO000952A ITTO20010952A1 (en) 2001-10-09 2001-10-09 USE OF TWO OR MORE GROWTH FACTORS THAT ACT ON CONTINUOUS STAGES OF CELL DIFFERENTIATION, ASSOCIATED WITH CIC ANTI-TUMOR DRUGS
ITTO2001A000952 2001-10-09

Publications (2)

Publication Number Publication Date
WO2003030928A2 WO2003030928A2 (en) 2003-04-17
WO2003030928A3 true WO2003030928A3 (en) 2003-12-11

Family

ID=11459247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011249 WO2003030928A2 (en) 2001-10-09 2002-10-08 Antitumor preparation

Country Status (2)

Country Link
IT (1) ITTO20010952A1 (en)
WO (1) WO2003030928A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739110A (en) * 1994-09-12 1998-04-14 Biomeasure Inc. Protection of hemopoietic cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739110A (en) * 1994-09-12 1998-04-14 Biomeasure Inc. Protection of hemopoietic cells

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHARRIER ET AL: "Red blood cells and high fluorescence reticuloytes production increased by induction chemotherapy and GM-CSF plus G-CSF in peripheral blood of breast cancer patients.", HEMATOL. CELL THER., vol. 42, 2000, pages 165 - 170, XP009005151 *
DE VRIES ET AL: "Recombinant human Interleukin-3 in clinical oncology", STEM CELLS, vol. 11, 1993, pages 72 - 80, XP009005237 *
FÄRBER ET AL: "Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin- 3", ANTI-CANCER DRUGS, vol. 8, 1997, pages 288 - 292, XP009005150 *
HAAS ET AL: "High dose therapy with peripheral blood progenitor cells support in patients with non hodgkins lymphoma", STEM CELLS, vol. 13, no. 3, 1995, pages 28 - 35, XP009005137 *
HEINZINGER ET AL: "Quality of Il-3 and G-CSF mobilized peripheral blood stem cells in patients with early chronic phase CML.", LEUKEMIA, vol. 12, 1998, pages 333 - 339, XP009005333 *
O'SHAUGHESSY ET AL: "A phase I study of sequential versus concurrent interleukin- 3 and granulocyte macrophage colony stimulating factor in advanced breast cancer patients treated with FLAC chemotherapy.", BLOOD, vol. 86, no. 8, 1995, pages 2913 - 2921, XP002230320 *
O'SHAUGHNESSY ET AL: "Prospective randomized trial of 5-fluorouracil leucovorin doxorubicin and cyclophosphamide chemotherapy in combination with the interleuin-3/granulocyte macrophage colony stimulating factor fusion protein (PIXY321) versus GM.CSF in patients with advanced breast cancer", BLOOD, vol. 87, no. 6, 1996, pages 2205 - 2211, XP009005142 *
PALMERI ET AL: "Prospective randomized trial of sequential interleukin-3 and granulocyte or granulocyte macrophage colony-stimulating factor after standard dose chemotherapy in cancer patients.", HEAMATOLOGICA, vol. 84, 1999, pages 1016 - 1023, XP009005224 *
PERILLO ET AL: "Peripheral blood progenitor cell collection after epirubicin, paclitaxol and cisplatin combination chemotherapy using EPO based cytokine regimes.", TRANSFUSION, vol. 41, May 2001 (2001-05-01), pages 674 - 680, XP009005226 *
VELDHUIS ET AL: "Pactitaxel ifofamide and cisplatin with granulocyte colony stimulating factor or recombinant human interleukin-3 and granuloyte colony stimulating factor in ovarian cancer", BRITISH JOURNAL OF CANCER, vol. 75, no. 5, 1997, pages 703 - 709, XP009005232 *

Also Published As

Publication number Publication date
ITTO20010952A1 (en) 2002-01-09
WO2003030928A2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
GB0017635D0 (en) Antitumor combined therapy
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
WO2001070275A3 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2002328953A1 (en) Use of irinotecan for improved treatment of cancer based on mdr1
IL159887A0 (en) Combination therapy for the treatment of cancer
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU2158601A (en) Antiviral agent for use in treatment of cancer
AU4373499A (en) Use of drug-loaded nanoparticles for the treatment of cancers
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
MXPA03008582A (en) Agents and methods for treatment of cancer.
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001222215A1 (en) Lumbago treating girdle
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
WO2003030928A3 (en) Antitumor preparation
AU2001257325A1 (en) Cancer treatment
ZA200203166B (en) Treatment of cancer.
AU2002316617A8 (en) Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
AU2002351382A1 (en) Combination cancer therapy
AU2001289127A1 (en) Tumor treatment
AU2001257168A1 (en) Cancer treatment
AU2001259160A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP